Association Between Serum Asprosin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus in the Community: A Cross-Sectional Study

Abstract

Objective To explore the association between serum asprosin and diabetic nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM) in the community. Methods In this cross-sectional study, we retrospectively collected the clinical data of T2DM patients from a community health service center in southeastern Shanxi Province between November 2019 and July 2021. Logistic regression analysis was used to calculate the odds ratio (OR) and the 95% confidence interval (95% CI) of asprosin levels on the risk of DN. Results Among 498 T2DM patients included in this study, 221 had microalbuminuria, 105 had massive albuminuria, and 172 did not have any signs of nephropathy. Serum asprosin level was positively correlated with diastolic blood pressure, body mass index, triglycerides, aspartate aminotransferase, alanine aminotransferase, creatinine, ACR and albumin-to-creatinine ratio (all P < 0.05) and negatively correlated with low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting plasma glucose, HbA1c and estimated glomerular filtration rate (all P < 0.05). After adjusting for covariates, increased asprosin was associated with diabetic nephropathy (all OR = 2.560, 95% CI: 1.1592–4.116; P < 0.001). Conclusion The risk of DN significantly increases with serum asprosin levels, especially among female patients.

Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects

“…Literature data showed a potential link between high circulating asprosin and uncontrolled diabetes that usually displays microvascular diabetic complications such as nephropathy, retinopathy, and peripheral neuropathy ( Table 4 ). As expected, circulating asprosin levels were significantly enhanced in T2DM patients with diabetic complications ( 67 , 68 , 70 , 71 ). Diabetic nephropathy (DN) (also known as diabetic kidney disease), a common severe complication of both types of diabetes mellitus, is considered a major cause of end-stage renal failure that seriously affects diabetic patients’ quality of life ( 76 ).…”

Asprosin, a prospective biomarker for rhabdomyolysis-induced acute kidney damage in rats: involvement of PKA/TGF-β1/SMAD-3 signaling pathway

“…Recently, the expression of asprosin in kidney tissues was reported [8]. Many studies demonstrated the changes in asprosin levels and their association with renal function in diabetic nephropathy cases that involved several pathogenic mechanisms [9][10][11]. The present study is the first in demonstrating the changes in asprosin levels in a rhabdomyolysisinduced AKI rat model.…”

“…Asprosin has been shown to have an inflammatory effect as it correlated positively with inflammatory cytokines and upregulated the inflammatory JNK phosphorylation TLR4-dependent pathway [9]. Also, it was found that increased levels of circulating asprosin were associated with diabetic nephropathy and that asprosin may affect renal homeostasis via several pathogenic mechanisms such as inflammation, insulin resistance, and endothelial dysfunction [9][10][11].…”

The correlation between serum asprosin and left ventricular diastolic dysfunction in elderly patients with type 2 diabetes mellitus in the community

“…Additionally, an elevated level of asprosin also increases the risk of diabetic retinopathy 6 and diabetic nephropathy 7 . Further studies by our research group have found that the risk of diabetic nephropathy caused by elevated asprosin was closely related to gender, especially being female 8 . Nevertheless, its specific mechanisms are not yet fully understood.…”